Exact Sciences schedules third-quarter 2018 earnings call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Exact Sciences (EXAS) Defended at Leerink
October 10, 2018 12:27 PM EDTLeerink Partners analyst Puneet Souda weighed in on Exact Sciences (NASDAQ: EXAS) saying the liquidy biopsy CRC screening tests are worth watching but are far from commercialization.
The analyst reiterated an Outperform and price target of $90.
For an analyst ratings... More
